Literature DB >> 7846367

The role of laryngeal mask airway in cardiopulmonary resuscitation.

A H Samarkandi1, M A Seraj, A el Dawlatly, M Mastan, H B Bakhamees.   

Abstract

The laryngeal mask airway (LMA) has been newly introduced to anaesthesia practice as an alternative to the endotracheal tube (ETT) or face mask for airway management. It is capable of providing a rapid and easily achieved patent airway that permits positive pressure ventilation within confined limits. In this study, we aim to evaluate the role of the LMA in cardiopulmonary resuscitation (CPR) in 20 patients as an alternative to tracheal intubation. Study parameters included measurement of oxygen saturation by a pulse oximeter and end-tidal carbon dioxide level (ETCO2) using the Fenem CO2 analyser. Five of these 20 cases were resuscitated using endotracheal tubes as a control group. Seven cases were resuscitated using LMA only and eight cases were resuscitated using LMA initially followed by ETT for long term ventilation. In the LMA groups I and III, 12 patients had LMA inserted at the first attempt and three at a second attempt. We concluded that LMA is a good alternative to ETT, although it may not protect against aspiration. We recommend it to be included in CPR chart cards and all medical doctors, nurses and paramedical staff should learn how to use it.

Entities:  

Mesh:

Year:  1994        PMID: 7846367     DOI: 10.1016/0300-9572(94)90080-9

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  2 in total

Review 1.  [Methods of airway management in prehospital emergency medicine].

Authors:  W Keul; M Bernhard; A Völkl; R Gust; A Gries
Journal:  Anaesthesist       Date:  2004-10       Impact factor: 1.041

2.  Effect of different types of laryngeal mask airway placement on the right internal jugular vein: A prospective randomized controlled trial.

Authors:  Jing-Jing Zhang; Zong-Yang Qu; Zhen Hua; Ming-Zhang Zuo; Hong-Ye Zhang
Journal:  World J Clin Cases       Date:  2019-12-26       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.